US › Healthcare

Purple Biotech (PPBT)

US · Healthcare · Biotechnology

$1.50+2.04%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-86,000

Profit YoY

+81.0%

EPS

$-2.33

EPS estimate

$-0.38

EPS came in at -2.33 against a street estimate of -0.38 — a miss of 512.4%.

Key statistics

Market cap

$1.3M

P/E

0.0

Forward P/E

0.0

P/B

0.13

Book value

$10.00

EPS (TTM)

$3,226.00

52-week high

$24.00

52-week low

$1.33

50-day MA

$1.98

200-day MA

$4.91

Beta

-0.55

Analyst view

Analysts rate Purple Biotech a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $30.00.

Shareholding

Insiders

3.74%

Institutions

6.56%

Largest institutional holders

Fund	Stake
Susquehanna International Group, LLP	5.73%
SmartHarvest Portfolios, LLC	1.94%
BNP Paribas Arbitrage, SA	0.21%
Rhumbline Advisers	0.08%
SIMPLEX TRADING, LLC	0.06%
Morgan Stanley - Brokerage Accounts	0.06%
UBS Group AG	0.01%
SBI Securities Co Ltd	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Purple Biotech — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.